4.1 Article

A randomized, double-blind, crossover trial of modafinil on mood

Journal

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
Volume 27, Issue 1, Pages 76-79

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/jcp.0b013e31802eb7ea

Keywords

-

Funding

  1. NCRR NIH HHS [RR00095] Funding Source: Medline
  2. NHLBI NIH HHS [1P01 HL56693, 1R01 HL67232] Funding Source: Medline
  3. NIMH NIH HHS [MH01741] Funding Source: Medline

Ask authors/readers for more resources

Modafinil, a medication for the excessive sleepiness associated with narcolepsy, has been hypothesized to improve not just alertness but mood as well. The purpose of this study was to determine how treatment with modafinil affects mood in healthy volunteers. Normal healthy volunteers (n = 12, 10 men and 2 women; 30-44 years) underwent a 3-day, counterbalanced, randomized, crossover, inpatient trial of modafinil (400 mg daily) versus placebo with 4-day washout period between 2 treatments. Mood was assessed daily using both the Positive and Negative Affect Schedule and a general mood scale, which consisted of 10 bipolar adjective ratings based on a severity scale ranging from 1 to 10. Modafinil increased general mood and Negative Affect scales relative to placebo and had a significant effect on Positive Affect scales. These results suggest that modafinil may have general mood-elevating effects accompanied by increased negative affect (anxiety). The findings may have implications for clinical practice, in particular for the adjunctive use of modafinil in treatment-resistant depression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available